Teikoku Seiyaku has established a business base in Europe
    (15th June 2001) (→ 日本語版リリース

Teikoku Seiyaku Co., Ltd. has established Teikoku Seiyaku London Office in London, UK to maintain good relationship with the European partners already we have, to gather much information, and to look for new partners for introduction of new products into Japan and of our products into European countries.

At the same time, Teikoku Seiyaku Co., Ltd. has established Teikoku Pharma UK Ltd. as the wholly owned subsidiary of Teikoku Pharma USA, Inc.(California, U.S.A.) at the same location.

Teikoku Pharma UK, Ltd. will mainly proceed with development of LIDODERM in Europe. LIDODERM, a patch transdermal delivery system with an indication specifically for the treatment of pain associated with postherpetic neuralgia (PHN), was launched in September of 1999 and has been distributed in USA by Teikoku Pharma USA, Inc. In addition, Teikoku Pharma UK, Ltd. will be representative of Teikoku Pharma USA, Inc. to support the development of the other products which are developed in USA.

Trade amount of Teikoku Seiyaku Co., Ltd. with European companies was approximately two billion Japanese Yen in 2000. Teikoku Seiyaku Co., Ltd. achieved the introduction of Dovonexointment for the treatment of psoriasis vulgaris from Europe into Japan, co-marketing with Fujisawa Pharmaceutical Co., Ltd. and Teikoku Medix Co., Ltd.

Reference Data
Teikoku Seiyaku London Office
Suite 7-9, Central House, 1 Ballards Lane, Finchley, London N3 1LQ. UK
Teikoku Pharma UK, Ltd.
Suite 7-9, Central House, 1 Ballards Lane, Finchley, London N3 1LQ. UK
Okitsugu Konishi, President & CEO
capital; 10,000 GBP
INDEXに戻る
TOPWhat's 帝國製薬製品情報会社情報採用情報医療関係者のみなさまニュースリリースサイトマップ
Copyright (C) 2008 Teikoku Seiyaku co.,ltd. All Rights Reserved.